文献速递膀胱癌与上尿路尿路上皮癌

帕博利珠单抗再治疗用于对一线帕博利珠单抗为基础治疗有应答的晚期或转移性尿路上皮癌患者

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
PubMed 文献 · Eur Urol · 2024-12-21

该事后分析评估了在KEYNOTE-045、KEYNOTE-052或KEYNOTE-361中接受帕博利珠单抗治疗、达到完全缓解后停药或完成35周期治疗且客观缓解或疾病稳定的晚期/转移性尿路上皮癌患者的帕博利珠单抗再治疗。49例患者纳入,再治疗客观缓解率41%,中位缓解持续时间14.0个月,中位无进展生存期9.5个月,中位总生存期25.7个月,治疗相关不良事件发生率45%。

要点

  • 再治疗客观缓解率41%,其中65%对一线治疗达完全缓解。
  • 再治疗中位无进展生存期9.5个月,中位总生存期25.7个月。
  • 治疗相关不良事件45%,3-4级6%,5级0%。

核心结论

  • 数据提示帕博利珠单抗再治疗对既往达完全缓解或完成2年帕博利珠单抗治疗的晚期/转移性尿路上皮癌部分患者有益且可耐受。

研究设计与样本

  • KEYNOTE-045、KEYNOTE-052或KEYNOTE-361的事后分析,纳入49例晚期/转移性尿路上皮癌患者。
  • 患者在完全缓解后停止帕博利珠单抗或完成35周期(约2年)治疗且客观缓解或疾病稳定,疾病进展后接受方案规定的帕博利珠单抗再治疗200 mg静脉每3周一次,≤17周期。

主要发现

  • 中位随访24.4个月(范围1.4-53.5),首次治疗停止至再治疗的中位时间10.7个月(范围1.0-36.3)。
  • 20例(41%)再治疗达客观缓解,其中65%对一线治疗达完全缓解。
  • 再治疗中位持续时间8.3个月(范围0.0-13.2),中位缓解持续时间14.0个月(2.1+至20.5)。
  • 自再治疗开始,中位(95%CI)无进展生存期9.5个月(5.6-15.0),中位总生存期25.7个月(21.5-27.5)。
  • 治疗相关不良事件发生率45%(3-4级6%,5级0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with metastatic solid tumors who previously had stable disease or a response with immunotherapy may derive benefit from immunotherapy retreatment. This post hoc analysis evaluated pembrolizumab retreatment in patients with advanced/metastatic urothelial carcinoma who received pembrolizumab in KEYNOTE-045, KEYNOTE-052, or KEYNOTE-361, and either stopped pembrolizumab after a complete response (CR) or completed pembrolizumab (35 cycles [∼2 yr]) with an objective response or stable disease. Upon disease progression, protocol-specified pembrolizumab retreatment (200 mg intravenously every 3 wk) was administered for ≤17 cycles. Forty-nine patients met the criteria and were included. The median follow-up was 24.4 mo (range, 1.4-53.5). The median time between first-course therapy cessation and pembrolizumab retreatment was 10.7 mo (1.0-36.3). Twenty patients (41%) had an objective response with pembrolizumab retreatment, 65% of whom had a CR to first-course treatment. The median retreatment duration was 8.3 mo (range, 0.0-13.2); the median duration of response was 14.0 mo (2.1+ to 20.5). From retreatment initiation, the median (95% confidence interval) progression-free survival and overall survival were 9.5 mo (5.6-15.0) and 25.7 mo (21.5-27.5), respectively. Treatment-related adverse events occurred in 45% (grade 3-4: 6%; grade 5: 0%). Data suggest that pembrolizumab retreatment is beneficial and tolerable for some patients with advanced/metastatic urothelial carcinoma who previously had a CR or completed 2 yr of pembrolizumab.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Koshkin VS, Danchaivijitr P, Bae WK, et al. Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy. Eur Urol. 2024. PMID: 39709248. doi:10.1016/j.eururo.2024.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。